HPHaridarshan Patel

Haridarshan Patel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Haridarshan Patel has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation and Development of Claims-Based Algorithms for Identifying Thyroid Eye Disease Using the IRIS Registry-Komodo Linked Database

    by Junjie Ma, Wendy W. Lee, Maurice Alan Brookhart, Madhura A. Tamhankar, Juan Ayala-Haedo, Fang He, Haridarshan Patel

    Objectives: To validate claims-based algorithms for identifying thyroid eye disease (TED) cases and assess whether machine learning can improve case identification in a large, linked real-world dataset. Methods: Using a large, linked database from Komodo Health® and Academy IRIS® Registry, we evaluated six rule-based algorithms incorporating Graves’ disease (GD), eye symptoms and signs. The IRIS Registry’s curated data, based on confirmed TED diagnoses from medical notes, served as the reference standard. Additionally, we developed supervised machine learning models using demographic, diagnostic, procedural, and medication data. Feature selection was performed using recursive feature elimination to rank predictive codes and construct a simplified, interpretable model. Cross-validation was used to assess model performance and compare performance with the rule-based algorithms. Results: The rule-based algorithms demonstrated a trade-off between sensitivity and specificity, with some achieving high specificity but limited sensitivity. Algorithm 1 had the highest sensitivity (48.7%) but lower specificity (59.9%) and PPV (75.8%). Algorithms 2–5 demonstrated higher specificity (87.2–93.5%) but lower sensitivity (17.8–27.0%). Algorithm 6 improved sensitivity (33.4%) compared to Algorithms 2–5 while maintaining high specificity (86.8%) and a strong PPV (86.7%). Machine learning models demonstrated similar trade-offs. One model achieved improved specificity (77.2%) with sensitivity of 49.3%, outperforming Algorithm 1 in specificity while matching its sensitivity. Another model maximized specificity (91.7%) and PPV (89.8%) at a reduced sensitivity of 28.5%. These results highlight the flexibility of machine learning models in adjusting performance to address different research objectives. Conclusions: This study evaluated existing rule-based algorithms for identifying TED cases in claims data, revealing trade-offs between sensitivity and specificity. Machine learning models provide additional flexibility, allowing performance to be tailored to specific research use cases. While no single method consistently outperformed others across all metrics, both rule-based and machine learning approaches demonstrated value in improving TED case identification using real-world data sources.

  • Open Access

    The Impact of Uncontrolled Gout on Healthcare Utilization and Health Outcomes for United States Veterans Affairs Patients

    by Adriana Vargus, Corbyn M. Gilmore, Jim M. Koeller, Grace C. Lee, Haridarshan Patel, Brian LaMoreaux, Xavier F. Jones, Christopher R. Frei

    Introduction Gout is an inflammatory arthritis that, when uncontrolled, can lead to chronic pain, disability, increased demand for healthcare, and poor health outcomes. This study sought to identify patients with gout and to describe the differences in epidemiology, pharmacotherapy, healthcare utilization, and outcomes for patients with controlled and uncontrolled gout in the United States (US) Veterans Affairs (VA) healthcare system. Methods This retrospective cohort study used electronic health record (EHR) data from VA patients from all US states and territories with gout from 1/1/2016 to 12/31/2022. The study included adult VA patients (18 +) with a diagnosis code for gout (ICD10 codes M10 or M1A) and two or more encounters 30 or more days apart. Uncontrolled gout was defined as one serum uric acid level (sUA) level > 8 mg/dl, tophi, or both in the study period. Results Of the 331,664 patients who met study criteria, 42% (138,068) were considered to have uncontrolled gout and 58% (193,596) were controlled. The uncontrolled group was younger (mean age 64 vs. 70 years, p < 0.01), and both groups were predominantly white non-Hispanic (58% and 70%) and male (99% and 99%). Specialist visits were more common in the uncontrolled group during follow-up: podiatry (38% vs. 30%, p < 0.01), rheumatology (24% vs. 9%, p < 0.01), and nephrology (24% vs. 12%, p < 0.01). Patients with uncontrolled gout were also significantly more likely to be seen in the emergency room (55% vs. 38%, p < 0.01) or admitted to the hospital (47% vs. 37%, p < 0.01) during follow-up. Conclusions Nearly half of VA patients with gout met criteria for uncontrolled gout, and these patients experienced greater healthcare utilization and worse health outcomes than patients with controlled gout. Patients with uncontrolled gout could benefit from additional/alternative approaches such as the adoption of a treat-to-target strategy and increasing referrals to a specialist.

  • Open Access

    Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison

    by George J Kahaly, Ann Xi, Naina Barretto, Haridarshan Patel, Anahita Qashqai, Mostafa Shokoohi, Paul Spin, Robert J Holt

    Context: Teprotumumab and/or intravenous methylprednisolone (IVMP) are first-line treatments for thyroid eye disease (TED)/Graves’ orbitopathy. Direct comparisons of these treatments on Graves’ Orbitopathy Quality of Life Questionnaire (GO-QoL) are lacking. Objective: Systematic review, meta-analysis, and matching-adjusted indirect treatment comparison (MAIC) of GO-QoL improvements. Methods: A literature search was performed using PubMed and Embase between inception to April 1, 2023, including studies of patients with moderate to severe active TED treated with teprotumumab or IVMP. Changes in GO-QoL scores and appearance and visual function subscales were extracted. Two teprotumumab (n = 84) and placebo (n = 87) randomized clinical trials and 5 studies with IVMP (4.5 mg/12 weeks, n = 304) were identified. MAIC compared teprotumumab/placebo by adjusting for baseline GO-QoL, diplopia, proptosis, smoking, age, and sex. Significant improvements in overall GO-QoL were observed for teprotumumab vs IVMP [mean difference (MD): 13.26; 95% confidence interval (CI): 7.44, 19.09) and placebo (MD: 12.57; 95% CI: 5.94, 19.21), but not IVMP vs placebo (MD: −2.06; 95% CI: −8.24, 4.12). Improvements were noted in appearance subscale GO-QoL for teprotumumab vs IVMP (MD: 7.50; 95% CI: 0.35, 14.64) and placebo (MD: 10.80; 95% CI: 3.62, 17.98) but not for IVMP vs placebo (MD: 0.91; 95% CI: −6.36, 8.18). Visual subscale GO-QoL displayed greater improvements for teprotumumab vs IVMP (MD: 17.66; 95% CI: 7.86, 27.47) and placebo (MD: 14.54; 95% CI: 6.10, 22.99), with no significant change for IVMP vs placebo (MD: −3.65; 95% CI: −12.88, 5.57). Orbital pain, teprotumumab treatment, diplopia, proptosis, and male sex were significant independent predictors of overall GO-QoL (P < .05). Conclusion: This unique analysis demonstrated a more clinically meaningful improvement in the health-related quality of life, as measured by the GO-QoL, for TED patients with teprotumumab vs both the most recommended IVMP dosage and placebo.


  • Open Access

    Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study

    by Stefan Schreiber, Brian G. Feagan, Edouard Louis, Tadakazu Hisamatsu, Toshifumi Hibi, Louis Dron, Corinne Jamoul, Haridarshan Patel, Kristina Harris, Virginia Taliadouros, et al.

    Background: Filgotinib is an oral, once‐daily, Janus kinase 1 preferential inhibitor approved for treatment of ulcerative colitis (UC) following the phase 2b/3 SELECTION trial. Identification of patient populations and factors associated with long‐term treatment response trajectories may improve UC management.Objective: We aimed to identify and describe distinct patient subgroups of response to filgotinib based on partial Mayo Clinic Score (pMCS) trajectories over time.Methods: In these post hoc analyses of SELECTION, group‐based trajectory modeling (GBTM) was applied to pMCS to describe groups of distinct, symptom‐based patient trajectories using data from patients who responded to filgotinib 200 or 100 mg and continued receiving filgotinib up to week 58. Patient demographics, disease characteristics, and week 10 response were compared between the groups. Achievement of a patient‐level multi‐component endpoint of comprehensive disease control (CDC) was assessed in each group.Results: GBTM identified five distinct patient populations with different response trajectories; 67.5% of patients had beneficial trajectories. The beneficial trajectory groups generally had higher proportions of patients who were recently diagnosed (50% decrease in FCP from baseline). Sustained beneficial trajectory groups had a higher probability of achieving CDC at week 58 than other groups (31%–32% vs. 0%–7%).Conclusions: Beneficial long‐term response trajectories and achievement of CDC with filgotinib were associated with being biologic‐naive and having less severe disease at baseline. Early estimation of sustained and CDC may facilitate patient identification and development of personalized management strategies in UC.ClinicalTrials.gov Identifier: NCT02914522.


  • Open Access

    Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey

    by Johan Burisch, Ailsa Hart, Andreas Sturm, Christine Rudolph, Rachael Meadows, Anna Jus, Fatima Dawod, Haridarshan Patel, Alessandro Armuzzi

    Background: Understanding disease burden is imperative for improving inflammatory bowel disease (IBD) management. This real-world survey investigated residual disease burden and treatment satisfaction among European patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). Methods: The Adelphi Real World IBD Disease Specific Programme was a multinational, cross-sectional survey with retrospective collection of patient- and physician-reported data on disease burden and management. Between October 2020 and March 2021, participating gastroenterologists recruited their next 7 (UC) and 8 (CD) eligible patients and reported demographics and clinical characteristics. Patients completed symptom, health-related quality of life (HRQoL), and treatment satisfaction questionnaires. Data were adjusted for confounding variables and compared between patients in remission (clinical remission, endoscopic remission, or both) and not in remission. Results: Overall, 1040 patients (UC, n = 502; CD, n = 538) were included. Although most patients were in remission (UC, 66.1%; CD, 69.5%), most still reported symptoms (UC, 63.7%; CD, 74.1%), including flatulence, fatigue/tiredness, and abdominal pain/distension. In UC, there were no significant differences in the likelihood of experiencing 7 of 23 symptoms between patients in remission and not in remission. In CD, there was no significant difference in 19 of 23 symptoms between patients in remission and not in remission. Several symptoms were significantly associated with reduced HRQoL. HRQoL was significantly better among patients in remission than not in remission. Conclusions: Patients with IBD, both in remission and not in remission, experience residual symptoms that impair HRQoL. Comprehensive endpoints, incorporating HRQoL and patients’ perspectives, and improved treatments are needed to address residual disease and patients’ needs.


  • Open Access

    Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany

    by Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin, Haridarshan Patel

    Purpose: Many patients treated for ulcerative colitis (UC) do not achieve clinical remission. This real-world study assessed clinical remission and inadequate response rates among patients with UC in Germany treated with advanced therapies. Methods: This retrospective chart review included patients with UC newly initiating advanced (index) therapy (anti-TNFα agents, vedolizumab, tofacitinib) from January 2017–September 2019 (index date). Included patients had data for ≥ 12 months before (baseline period) and after the index date (follow-up period). Remission was defined as a partial Mayo score ≤ 1. Indicators of inadequate response were: index therapy discontinuation; therapy adjustments (index therapy dose escalation; augmentation with non-advanced therapies; corticosteroid [CS] use during maintenance therapy); CS dependency (use for ≥ 12 weeks); and UC-related hospitalisation, surgery or emergency department visit. Time to first remission and inadequate response were analyzed using Kaplan–Meier analyses. Results: Among 149 patients with UC (median age: 40 years), 96 (64.4%) were biologic-naïve and 42 (28.2%) received CS at the index date. Within 12 months, 52 patients (47.2%) were in remission; of these, 13 patients (25.0%) received ≥ 1 therapy adjustment. At 12 months, 55 patients (37.6%) had ≥ 1 indicator of an inadequate response. Median time to remission was longer among biologic-experienced vs biologic-naïve patients (24 vs 7 months; p = 0.012). Conclusion: Over half of the patients were not in clinical remission after 12 months and more than one-third experienced inadequate response. One-quarter of patients in remission required therapy adjustments. Patients with UC require therapies that are more effective than those currently available to achieve better treatment outcomes.


  • Open Access

    The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom

    by James O. Lindsay, Nils Picker, Daniel Kromer, Michael Smyth, Haridarshan Patel

    Treatment of ulcerative colitis (UC) follows a stepwise approach that considers disease severity and disease activity. It has the goal of achieving and maintaining steroid-free remission and healing of the gut lining. Treatment options for UC include several conventional and advanced therapies. However, suboptimal response to treatment has been reported in previous observational studies. This results in treatment adjustments, such as therapy discontinuation, dose intensification and addition of conventional therapies, as well as lengthy concurrent use of corticosteroids. This retrospective chart review evaluated clinical practice data from eight clinics across the United Kingdom. This was done to assess rates of clinical remission and indicators of suboptimal response to advanced therapies among patients with UC. Analysis included data from January 2017 to September 2019. Nearly half of patients did not have clinical remission within one year after starting advanced therapies. Optimization of advanced therapies was often seen, even in patients in remission. The most common indicators of suboptimal therapy were therapy discontinuation, dose escalation of advanced therapy, and addition of conventional therapies. Our findings suggest that efficacy of advanced therapies to treat UC remains insufficient in clinical practice. Thus, there is a need for more effective treatment alternatives to achieve better outcomes for patients with UC.


  • P45 Combining clinical, biological, and health-related quality of life remission with endoscopic improvements: data from SELECTION

    by Ben Morison, Stefan Schreiber, Brian Feagan, Laurent Peyrin-Biroulet, Severine Vermeire, Margaux Faes, Alessandra Oortwijn, Patrick Daniele, Haridarshan Patel, Silvio Danese

    Introduction For patients with UC, both subjectively and objectively reported measures are equally important treatment goals. We explored clinical, biological, HRQoL remission and endoscopic improvements as a combined endpoint (CE) from SELECTION (NCT02914522), a phase 2b/3 double-blind trial of filgotinib (FIL), a once-daily, oral, JAK1 preferential inhibitor, for the treatment of UC. Methods In SELECTION, patients with moderately to severely active UC were randomized 2:2:1 to FIL 200mg or 100mg (FIL200/100) or placebo (PBO) for an 11-week induction phase followed by a 47-week maintenance period in patients who achieved clinical remission or response. We defined a CE as achieving all of: 1) clinical remission defined as partial Mayo Score (excluding endoscopy domain) ≤2 and no subscore >1, 2) biological remission defined as faecal calprotectin 170 and 4) endoscopic improvement defined as Mayo endoscopic subscore ≤1. We evaluated the CE in patients treated with FIL200 vs PBO at week 10 and 58. Among those achieving the CE, we analysed MCID improvement during induction and decline during maintenance on generic QoL instruments (SF-36 and EQ5D). Results Overall population included 381 biologic-naïve and 401 biologic-experienced patients undergoing induction, of whom 297 entered maintenance. A higher proportion of patients receiving FIL200 achieved CE than PBO by week 10 in the biologic-naïve cohort (17.6% vs 4.41%, ptable 1). Biologic-naïve CE achievers had higher MCID improvement across all generic QoL scales and domains. Patients achieving CE in maintenance experienced a lower proportion of MCID decline in EQ5D utility, and visual analogue scale. Conclusion Treatment with FIL resulted in a higher proportion of patients with combined clinical, biological, HRQoL remission and endoscopic improvements. Among patients achieving this combined composite endpoint, clinically meaningful improvements were observed in their overall QoL. Holistic assessment of several subjective and objective measures may help achieve better outcomes in UC. Proportion of patients achieving CE at week 10 and 58

  • P49 Indicators for inadequate response to advanced therapy in ulcerative colitis: a UK medical chart review

    by Ben Morison, Nils Picker, Michael Smyth, Haridarshan Patel, Daniel Kromer

    Introduction Patients with UC commencing advanced therapy may experience inadequate response or require therapy modification to achieve remission. Therapeutic modification increases healthcare costs and is associated with adverse events. This study aimed to examine the rates of inadequate response, therapeutic modification and subsequent remission among UC patients starting advanced therapy in the UK. Methods Using a retrospective chart review, patients with UC treated with an advanced therapy (adalimumab, infliximab, golimumab, vedolizumab, tofacitinib) during 01/2017–09/2019 were selected from 8 UK clinics. Patients with ≥12 months of data before and after starting an advanced therapy (Index Date) were included. Inadequate response was defined as >1 event of: index therapy discontinuation or switch due to lack of response, therapy escalation, augmentation with an additional conventional therapy, corticosteroid (CS) dependency (use for ≥12 weeks), new CS initiation, UC-related hospitalisation, surgery, or emergency department visit. Remission was assessed using Mayo score components. Kaplan-Meier analysis examined remission rates over 24 months. Subgroups included patients with prior exposure to biologics, and patients with vs without remission at 12 months. Factors associated with time to remission were assessed in a multivariate Cox regression model. Results Among 238 patients included (female: 46.6%; median 42 years; median follow-up: 28.8 months), 178 (74.8%) patients were biologic-naïve and 60 (25.2%) were biologic-experienced. At 12 months, 105 (44.3%) patients had experienced ≥1 indicator for an inadequate response (Figure 1); median time to first event was 18 months. Among those who discontinued (N=72), 69.4% switched to another advanced therapy. Inadequate response was more frequent in biologic-naïve vs experienced patients (50.3% vs. 26.7%; pConclusion More than two-fifths of UC patients had an inadequate response, and nearly half did not achieve remission within 1 year after therapy start. Even among patients in remission, one-third required additional therapy modifications. More effective therapies are needed to achieve better outcomes for patients with UC. Indicators of inadequate response among patients with UC

  • Open Access

    Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis

    by Toshifumi Hibi, Isao Kamae, Philippe Pinton, Lyann Ursos, Ryuichi Iwakiri, Greg Hather, Haridarshan Patel

    Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses.Methods: A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologicnaïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6–12) and maintenance (weeks 30–60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results across all trials were estimated using network meta-analyses followed by transformation into probabilities and odds ratios (OR).Results: At the end of induction, the likelihood of clinical response and clinical remission was highest with infliximab (OR: 2.12 and 2.35, respectively) and vedolizumab (OR: 2.10 and 2.32, respectively); the likelihood of mucosal healing was highest with infliximab (OR: 2.24) and adalimumab (OR: 1.86). During maintenance, the likelihood of clinical response and clinical remission was highest with vedolizumab (OR: 6.44 and 4.68, respectively) and golimumab (OR: 5.13 and 3.84, respectively); the likelihood of mucosal healing was significantly higher than placebo with all biologics.Conclusions: All active treatments were efficacious compared with placebo. Infliximab and vedolizumab had the highest odds for induction of clinical response, remission, and mucosal healing. Golimumab and vedolizumab had numerically higher odds of achieving efficacy outcomes in the maintenance phase.